These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29091939)

  • 1. Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model.
    Scott AJ; Song EK; Bagby S; Purkey A; McCarter M; Gajdos C; Quackenbush KS; Cross B; Pitts TM; Tan AC; Eckhardt SG; Fenton H; Arcaroli J; Messersmith WA
    PLoS One; 2017; 12(11):e0187173. PubMed ID: 29091939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
    Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
    Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.
    Beadnell TC; Mishall KM; Zhou Q; Riffert SM; Wuensch KE; Kessler BE; Corpuz ML; Jing X; Kim J; Wang G; Tan AC; Schweppe RE
    Mol Cancer Ther; 2016 Aug; 15(8):1952-63. PubMed ID: 27222538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.
    Tokuhisa Y; Lidsky ME; Toshimitsu H; Turley RS; Beasley GM; Ueno T; Sharma K; Augustine CK; Tyler DS
    Ann Surg Oncol; 2014 Mar; 21(3):1024-30. PubMed ID: 24281418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
    Eustace AJ; Crown J; Clynes M; O'Donovan N
    J Transl Med; 2008 Sep; 6():53. PubMed ID: 18823558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.
    Gilani RA; Phadke S; Bao LW; Lachacz EJ; Dziubinski ML; Brandvold KR; Steffey ME; Kwarcinski FE; Graveel CR; Kidwell KM; Merajver SD; Soellner MB
    Clin Cancer Res; 2016 Oct; 22(20):5087-5096. PubMed ID: 27154914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells.
    Chen B; Xu X; Luo J; Wang H; Zhou S
    PLoS One; 2015; 10(6):e0129663. PubMed ID: 26061184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer.
    Baker AM; Cox TR; Bird D; Lang G; Murray GI; Sun XF; Southall SM; Wilson JR; Erler JT
    J Natl Cancer Inst; 2011 Mar; 103(5):407-24. PubMed ID: 21282564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.
    Zheng MW; Zhang CH; Chen K; Huang M; Li YP; Lin WT; Zhang RJ; Zhong L; Xiang R; Li LL; Liu XY; Wei YQ; Yang SY
    Mol Cancer Ther; 2016 Mar; 15(3):366-78. PubMed ID: 26721945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.
    Lieu CH; Klauck PJ; Henthorn PK; Tentler JJ; Tan AC; Spreafico A; Selby HM; Britt BC; Bagby SM; Arcaroli JJ; Messersmith WA; Pitts TM; Eckhardt SG
    Oncotarget; 2015 Oct; 6(33):34561-72. PubMed ID: 26439693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma.
    El Sayed I; Helmy MW; El-Abhar HS
    Life Sci; 2018 Nov; 213():248-257. PubMed ID: 30292831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
    Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
    Pitts TM; Bradshaw-Pierce EL; Bagby SM; Hyatt SL; Selby HM; Spreafico A; Tentler JJ; McPhillips K; Klauck PJ; Capasso A; Diamond JR; Davis SL; Tan AC; Arcaroli JJ; Purkey A; Messersmith WA; Ecsedy JA; Eckhardt SG
    Oncotarget; 2016 Aug; 7(31):50290-50301. PubMed ID: 27385211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.
    Klauck PJ; Bagby SM; Capasso A; Bradshaw-Pierce EL; Selby HM; Spreafico A; Tentler JJ; Tan AC; Kim J; Arcaroli JJ; Purkey A; Messersmith WA; Kuida K; Eckhardt SG; Pitts TM
    BMC Cancer; 2018 Feb; 18(1):136. PubMed ID: 29402316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.
    Arcaroli JJ; Touban BM; Tan AC; Varella-Garcia M; Powell RW; Eckhardt SG; Elvin P; Gao D; Messersmith WA
    Clin Cancer Res; 2010 Aug; 16(16):4165-77. PubMed ID: 20682712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.
    Perez M; Lucena-Cacace A; Marín-Gómez LM; Padillo-Ruiz J; Robles-Frias MJ; Saez C; Garcia-Carbonero R; Carnero A
    Oncotarget; 2016 May; 7(22):33111-24. PubMed ID: 27105527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer.
    Sun Y; Lin X; Aske JC; Ye P; Williams C; Abramovitz M; Leyland-Jones BR
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1241-1256. PubMed ID: 31541266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
    Ceppi P; Papotti M; Monica V; Lo Iacono M; Saviozzi S; Pautasso M; Novello S; Mussino S; Bracco E; Volante M; Scagliotti GV
    Mol Cancer Ther; 2009 Nov; 8(11):3066-74. PubMed ID: 19861409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.
    Truffaux N; Philippe C; Paulsson J; Andreiuolo F; Guerrini-Rousseau L; Cornilleau G; Le Dret L; Richon C; Lacroix L; Puget S; Geoerger B; Vassal G; Östman A; Grill J
    Neuro Oncol; 2015 Jul; 17(7):953-64. PubMed ID: 25534822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.